Prostate cancer is the most commonly diagnosed malignancy in the UK representing 24% of male cancers; the death rate from prostate cancer is significant at 3% of all male deaths.1 In many cases, the disease has a long period of asymptomatic growth before developing into locally advanced or metastatic disease with symptoms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
UK CR. Prostate Cancer Incidence Statistics UK. London: Cancer Research; 2007
Ahmed S. A history of cryosurgery. In: Mattelaer JJ, ed. de Historia Urologiae Europaeae. Vol 13. Belgium: Historical Committee EAU; 2006:145–155
Arnott J. Practical illustrations of the remidial efficacy of very low or anaesthetic temperature. I. In Cancer. Lancet. 1850;2:257–259
Cooper IS, Lee AS. Cryostatic congelation: a system for producing a limited, controlled region of cooling or freezing of biologic tissues. J Nerv Ment Dis. 1961;133:259–263
Gonder MJ, Soanes WA, Shulman S. Cryosurgical treatment of the prostate. Invest Urol. 1966;3(4):372–378
Onik GM, Cohen JK, Reyes GD, Rubinsky B, Chang Z, Baust J. Transrectal ultrasound-guided percutaneous radical cryosurgical ablation of the prostate. Cancer. 1993;72(4):1291–1299
Lee F, Bahn DK, McHugh TA, Onik GM, Lee FT Jr. US-guided percutaneous cryoablation of prostate cancer. Radiology. 1994;192(3):769–776
Cohen JK, Miller RJ, Shuman BA. Urethral warming catheter for use during cryoablation of the prostate. Urology. 1995;45(5):861–864
Larson TR, Rrobertson DW, Corica A, Bostwick DG. In vivo interstitial temperature mapping of the human prostate during cryosurgery with correlation to histopathologic outcomes. Urology. 2000;55(4):547–552
Seifert JK, Gerharz CD, Mattes F, et al A pig model of hepatic cryotherapy. In vivo temperature distribution during freezing and histopathological changes. Cryobiology. 2003;47(3):214–226
Gage AA. History of cryosurgery. Semin Surg Oncol. 1998;14(2):99–109
Whittaker DK. Mechanisms of tissue destruction following cryosurgery. Ann R Coll Surg Engl. 1984;66(5):313–318
Baust JG, Gage AA. Progress toward optimization of cryosurgery. Technol.Cancer Res Treat. 2004;3(2):95–101
Mazur P. Freezing of living cells: mechanisms and implications. Am J Physiol. 1984;247(3 pt 1):125–142
Bischof JC, Smith D, Pazhayannur PV, Manivel C, Hulbert J, Roberts KP. Cryosurgery of dunning AT-1 rat prostate tumor: thermal, biophysical, and viability response at the cellular and tissue level. Cryobiology. 1997;34(1):42–69
Hong JS, Rubinsky B. Patterns of ice formation in normal and malignant breast tissue. Cryobiology. 1994;42(1):59–68
Tatsutani K, Rubinsky B, Onik G, Dahiya R. Effect of thermal variables on frozen human primary prostatic adenocarcinoma cells. Urology. 1996;48(3):441–447
Cooper IS. Cryobiology as viewed by the surgeon. Cryobiology. 1964;51:44–51
Dow JA, Waterhouse K. An experimental study in lethal freezing temperatures of the prostate gland. J Urol. 1970;103(4):454–457
Klossner DP, Robilotto AT, Clarke DM, et al Cryosurgical technique: assessment of the fundamental variables using human prostate cancer model systems. Cryobiology. 2007;55(3):189–199
Gage AA, Baust J. Mechanisms of tissue injury in cryosurgery. Cryobiology. 1998;37(3):171–186
Baust JG, Gage AA. The molecular basis of cryosurgery. BJU Int. 2005;95(9):1187–1191
Poppendiek HF, Randall R, Breeden JA, Chambers JE, Murphy JR. Thermal conductivity measurements and predictions for biological fluids and tissues. Cryobiology. 1967;3(4):318–327
NICE. Interventional procedures overview of cryotherapy as a primary treatment for prostate cancer. London: National Institute of Clinical Excellence; 2005:1–15
Shelley M, Wilt TJ, Coles B, Mason MD. Cryotherapy for localised prostate cancer. Cochrane Database Syst Rev. 2007;(3):CD005010
Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS. Guideline for the management of clincially localised prostate cancer: 2007 update. J Urol. 2007;177:2106
Babaian RJ, Donnelly B, Bahn D, et al Best practice statement on cryosurgery for the treatment of localized prostate cancer. J Urol. 2008;180(5):1993–2004
Chin JL, Ng CK, Touma NJ, et al Randomized trial comparing cryoablation and external beam radiotherapy for T2C-T3B prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(1):40–45
Vicini FA, Kestin LL, Martinez AA. Prostatectomy, external beam radiation therapy, or brachytherapy for localized prostate cancer. JAMA. 1999;281(17):1583–1584; discussion 1585–1586
Potters L, Klein EA, Kattan MW, et al Monotherapy for stage T1–T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol. 2004;71(1):29–33
D’Amico AV, Crook J, Beard CJ, DeWeese TL, Hurwitz M, Kaplan I. In: Kavoussi LR, Novick AC, Partin AW, Peters CA, eds. Campbell’s Urology. Philadelphia: Saunders; 2007:3014–3031
NICE. Prostate Cancer: Diagnosis and Treatment. Cardiff: Velindre NHS Trust, Cardiff, Wales; 2008
Thompson I, Thrasher JB, Aus G, et al Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177(6):2106–2131
Partin AW, Kattan MW, Subong EN, et al Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA. 1997;277(18):1445–1451
Ghafar MA, Johnson CW, De La Taille A, et al Salvage cryotherapy using an argon based system for locally recurrent prostate cancer after radiation therapy: the Columbia experience. J Urol. 2001;166(4):1333–1337; discussion 1337–1338
Katz AE, Ghafar MA. Selection of salvage cryotherapy patients. Rev Urol. 2002;4(suppl 2):S18–S23
Dudderidge T, Payne H, Emberton M. An algorithm for managing the failure of external beam radiotherapy in prostate cancer. BJU Int. 2007;100(3):518–527
Chan TY, Chan DY, Stutzman KL, Epstein JI. Does increased needle biopsy sampling of the prostate detect a higher number of potentially insignificant tumors? J Urol. 2001;166(6):2181–2184
Ahmed S, Lindsey B, Davies J. Salvage cryosurgery for locally recurrent prostate cancer following radiotherapy. Prostate Cancer Prostatic Dis. 2005;8(1):31–35.
Blasko JC, Grimm PD, Sylsvester JE, Cavanagh W. The role of external beam radiotherapy with I-125/Pd-103 brachytherapy for prostate carcinoma. Radiother Oncol. 2000;57(3):273–278
Cohen JK, Miller RJ Jr, Ahmed S, Lotz MJ, Baust J. Ten-year biochemical disease control for patients with prostate cancer treated with cryosurgery as primary therapy. Urology. 2008;71(3):515–518
Hubosky SG, Fabrizio MD, Schellhammer PF, Barone BB, Tepera CM, Given RW. Single center experience with third-generation cryosurgery for management of organ-confined prostate cancer: critical evaluation of short-term outcomes, complications, and patient quality of life. J Endourol. 2007;21(12):1521–1531
Long JP, Bahn D, Lee F, Shinohara K, Chinn DO, Macaluso JN Jr. Five-year retrospective, multi-institutional pooled analysis of cancer-related outcomes after cryosurgical ablation of the prostate. Urology. 2001;57(3):518–523
Bahn DK, Lee F, Badalament R, Kumar A, Greski J, Chernick M. Targeted cryoablation of the prostate: 7-year outcomes in the primary treatment of prostate cancer. Urology. 2002;60(2 suppl 1):3–11
Polascik TJ, Nosnik I, Mayes JM, Mouraviev V. Short-term cancer control after primary cryosurgical ablation for clinically localized prostate cancer using third-generation cryotechnology. Urology. 2007;70(1):117–121
Donnelly BJ, Saliken JC, Ernst DS, et al Prospective trial of cryosurgical ablation of the prostate: five-year results. Urology. 2002;60(4):645–649
El Hayek OR, Alfer W Jr, Reggio E, Pompeo AC, Arap S, Srougi M. Percutaneous prostate cryoablation as treatment for high-risk prostate cancer. Clinics. 2007;62(2):109–112
Prepelica KL, Okeke Z, Murphy A, Katz AE. Cryosurgical ablation of the prostate: high risk patient outcomes. Cancer. 2005;103(8):1625–1630
Han KR, Cohen JK, Miller RJ, et al Treatment of organ confined prostate cancer with third generation cryosurgery: preliminary multicenter experience. J Urol. 2003;170(4 pt 1):1126–1130
Koppie TM, Shinohara K, Grossfeld GD, Presti JC Jr, Carroll PR. The efficacy of cryosurgical ablation of prostate cancer: the University of California, San Francisco experience. J Urol. 1999;162(2):427–432
Wong WS, Chinn DO, Chinn M, Chinn J, Tom WL. Cryosurgery as a treatment for prostate carcinoma: results and complications. Cancer. 1997;79(5):963–974
Shinohara K, Connolly JA, Presti JC Jr, Carroll PR. Cryosurgical treatment of localized prostate cancer (stages T1 to T4): preliminary results. J Urol. 1996;156(1):115–120; discussion 120–121
Miller RJ Jr, Cohen JK, Merlotti LA. Percutaneous transperineal cryosurgical ablation of the prostate for the primary treatment of clinical stage C adenocarcinoma of the prostate. Urology. 1994;44(2):170–174
Chin JL, Pautler SE, Mouraviev V, Touma N, Moore K, Downey DB. Results of salvage cryoablation of the prostate after radiation: identifying predictors of treatment failure and complications. J Urol. 2001;165(6 pt 1):1937–1941; discussion 1941–1942
de la Taille A, Hayek O, Benson MC, et al Salvage cryotherapy for recurrent prostate cancer after radiation therapy: the Columbia experience. Urology. 2000;55(1):79–84
Bahn DK, Lee F, Silverman P, et al Salvage cryosurgery for recurrent prostate cancer after radiation therapy: a seven-year follow-up. Clin Prostate Cancer. 2003;2(2):111–114
Connolly JA, Shinohara K, Carroll PR. Cryosurgery for locally advanced (T3) prostate cancer. Semin Urol Oncol. 1997;15(4):244–249
Pisters LL, von Eschenbach AC, Scott SM, et al The efficacy and complications of salvage cryotherapy of the prostate. J Urol. 1997;157(3):921–925
Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS. Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol. 2008;180(2):559–563; discussion 563–564
Ng CK, Moussa M, Downey DB, Chin JL. Salvage cryoablation of the prostate: followup and analysis of predictive factors for outcome. J Urol. 2007;178(4 pt 1):1253–1257; discussion 1257
Bales GT, Williams MJ, Sinner M, Thisted RA, Chodak GW. Short-term outcomes after cryosurgical ablation of the prostate in men with recurrent prostate carcinoma following radiation therapy. Urology. 1995;46(5):676–680
Pisters LL. Treatment failure after primary and salvage therapy for prostate cancer. Cancer. 2008;112(2):225–227
Gould RS. Total cryosurgery of the prostate versus standard cryosurgery versus radical prostatectomy: comparison of early results and the role of transurethral resection in cryosurgery. J Urol. 1999;162(5):1653–1657
Ismail M, Ahmed S, Kastner C, Davies J. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int. 2007;100(4):760–764
Perrotte P, Litwin MS, McGuire EJ, Scott SM, von Eschenbach AC, Pisters LL. Quality of life after salvage cryotherapy: the impact of treatment parameters. J Urol. 1999;162(2):398–402
Lam JS. Salvage cryosurgical ablation for radiorecurrent prostate cancer using third generation cryoneedles: the University of California-Los Angeles experience. J Urol. 2005;173:181
Robinson JW, Donnelly BJ, Coupland K, et al Quality of life 2 years after salvage cryosurgery for the treatment of local recurrence of prostate cancer after radiotherapy. Urol Oncol. 2006;24(6):472–486
Onik G. Rationale for a “male lumpectomy,” a prostate cancer targeted approach using cryoablation: results in 21 patients with at least 2 years of follow-up. Cardiovasc Intervent Radiol. 2008;31(1):98–106
Janzen NK, Han KR, Perry KT, Said JW, Schulam PG, Belldegrun AS. Feasibility of nerve-sparing prostate cryosurgery: applications and limitations in a canine model. J Endourol. 2005;19(4):520–525
Lambert EH, Bolte K, Masson P, Katz AE. Focal cryosurgery: encouraging health outcomes for unifocal prostate cancer. Urology. 2007;69(6):1117–1120
Romero-Mendez R, Franco W, Aguilar G. Laser-assisted cryosurgery of prostate: numerical study. Phys Med Biol. 2007;52(2):463–478
Cytron S, Paz A, Kravchick S, Shumalinski D, Moore J. Active rectal wall protection using direct transperineal cryo-needles for histologically proven prostate adenocarcinomas. Eur Urol. 2003;44(3):315–320; discussion 320–321
Jones JS. Ultrasound probe positioning to minimize the risk of recto-urethral fistula during cryosurgical ablation of prostate cancer. BJU Int. 2007;100(1):58–62; discussion 62
Clarke DM, Robilotto AT, VanBuskirk RG, Baust JG, Gage AA, Baust JM. Targeted induction of apoptosis via TRAIL and cryoablation: a novel strategy for the treatment of prostate cancer. Prostate Cancer Prostatic Dis. 2007;10(2):175–184
Clarke DM, Baust JM, Van Buskirk RG, Baust JG. Addition of anticancer agents enhances freezing-induced prostate cancer cell death: implications of mitochondrial involvement. Cryobiology. 2004;49(1):45–61
Goel R, Swanlund D, Coad J, Paciotti GF, Bischof JC. TNF-alpha-based accentuation in cryoinjury-dose, delivery, and response. Mol Cancer Ther. 2007;6(7):2039–2047
Gursel E, Roberts M, Veenema RJ. Regression of prostatic cancer following sequential cryotherapy to the prostate. J Urol. 1972;108(6):928–932
Soanes WA, Ablin RJ, Gonder MJ. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol. 1970;104(1):154–159
den Brok MH, Sutmuller RP, van der Voort R, et al In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64(11):4024–4029
Joosten JJ, Muijen GN, Wobbes T, Ruers TJ. In vivo destruction of tumor tissue by cryoablation can induce inhibition of secondary tumor growth: an experimental study. Cryobiology. 2001;42(1):49–58
Sabel MS, Nehs MA, Su G, Lowler KP, Ferrara JL, Chang AE. Immunologic response to cryoablation of breast cancer. Breast Cancer Res Treat. 2005;90(1):97–104
Friedman EJ, Orth CR, Brewton KA, Ponniah S, Alexander RB. Cryosurgical ablation of the normal ventral prostate plus adjuvant does not protect Copenhagen rats from Dunning prostatic adenocarcinoma challenge. J Urol. 1997;158(4):1585–1588
Hoffmann NE, Coad JE, Huot CS, Swanlund DJ, Bischof JC. Investigation of the mechanism and the effect of cryoimmunology in the Copenhagen rat. Cryobiology. 2001;42(1):59–68
Hayakawa K, Yamashita T, Suzuki K, et al Comparative immunological studies in rats following cryosurgery and surgical excision of 3-methylcholanthrene-induced primary autochthonous tumors. Gann. 1982;73(3):462–469
Moore FT, Blackwood J, Sazenbacher L, Pace WG. Cryotherapy for malignant tumors. Immunologic response. Arch Surg. 1968;96(4):527–529
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag London
About this chapter
Cite this chapter
Henderson, A., Ismail, M., Davies, J. (2010). Cryosurgical Ablation for Prostate Cancer. In: Dasgupta, P., Fitzpatrick, J., Kirby, R., Gill, I.S. (eds) New Technologies in Urology. New Techniques in Surgery Series, vol 7. Springer, London. https://doi.org/10.1007/978-1-84882-178-1_12
Download citation
DOI: https://doi.org/10.1007/978-1-84882-178-1_12
Publisher Name: Springer, London
Print ISBN: 978-1-84882-177-4
Online ISBN: 978-1-84882-178-1
eBook Packages: MedicineMedicine (R0)